 Pancreatic Neoplasms
"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Descriptor ID |
D010190
|
| MeSH Number(s) |
C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
|
| Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
- Neoplasms, Pancreatic
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 1 | 0 | 1 | | 1986 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1995 | 2 | 0 | 2 | | 1996 | 5 | 0 | 5 | | 1997 | 3 | 0 | 3 | | 1998 | 6 | 0 | 6 | | 1999 | 4 | 2 | 6 | | 2000 | 4 | 2 | 6 | | 2001 | 4 | 0 | 4 | | 2002 | 5 | 2 | 7 | | 2003 | 4 | 0 | 4 | | 2004 | 2 | 0 | 2 | | 2005 | 4 | 0 | 4 | | 2006 | 4 | 0 | 4 | | 2007 | 1 | 0 | 1 | | 2008 | 6 | 0 | 6 | | 2009 | 1 | 0 | 1 | | 2010 | 5 | 0 | 5 | | 2011 | 6 | 0 | 6 | | 2012 | 9 | 0 | 9 | | 2013 | 5 | 0 | 5 | | 2014 | 2 | 0 | 2 | | 2015 | 7 | 1 | 8 | | 2016 | 6 | 0 | 6 | | 2017 | 9 | 2 | 11 | | 2018 | 8 | 0 | 8 | | 2019 | 8 | 2 | 10 | | 2020 | 10 | 1 | 11 | | 2021 | 5 | 0 | 5 | | 2022 | 7 | 0 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Pijnappel EN, Suurmeijer JA, Koerkamp BG, Kos M, Siveke JT, Salvia R, Ghaneh P, van Eijck CHJ, van Etten-Jamaludin FS, Abrams R, Brasiuniene B, Büchler MW, Casadei R, van Laethem JL, Berlin J, Boku N, Conroy T, Golcher H, Sinn M, Neoptolemos JP, van Tienhoven G, Besselink MG, Wilmink JW, van Laarhoven HWM. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement. JAMA Oncol. 2022 06 01; 8(6):929-937.
-
Modi S, Giri B, Gupta VK, Lavania S, Sethi V, Sharma NS, Pandey S, Vickers S, Dudeja V, Saluja AK. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. Cancer Lett. 2022 07 01; 537:215591.
-
Lakiza O, Lutze J, Vogle A, Williams J, Abukdheir A, Miller P, Liao C', Pitroda SP, Martinez C, Olivas A, Setia N, Kron SJ, Weichselbaum RR, Keutgen XM. Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
-
Hammer L, Hausner D, Ben-Ayun M, Shacham-Shmueli E, Morag O, Margalit O, Boursi B, Yarom N, Jacobson G, Katzman T, Abrams R, Dicker A, Golan T, Symon Z, Lawrence YR. Single-Fraction Celiac Plexus Radiosurgery: A Preliminary Proof-of-Concept Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 Jul 01; 113(3):588-593.
-
Keutgen XM. First Differentiate and Then Operate (Or Not) : Editorial on "Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis". Ann Surg Oncol. 2022 06; 29(6):3371-3372.
-
Haque MR, Barlass U, Armstrong A, Shaikh M, Bishehsari F. Novel role of the Mu-opioid receptor in pancreatic cancer: potential link between opioid use and cancer progression. Mol Cell Biochem. 2022 May; 477(5):1339-1345.
-
Sharma AE, Olivas A, Parilla M, Yassan L, Wang H, Zhang SS, Weber C, Keutgen XM, Hart J, Krausz T, Setia N. Epigenetic Dysregulation of 5-hydroxymethylcytosine in Well-Differentiated Pancreatic Neuroendocrine Tumors. Appl Immunohistochem Mol Morphol. 2022 02 01; 30(2):e11-e15.
-
Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer. 2022 02 01; 128(3):435-446.
-
Keutgen XM, Ornell KJ, Vogle A, Lakiza O, Williams J, Miller P, Mistretta KS, Setia N, Weichselbaum RR, Coburn JM. Sunitinib-Loaded Chondroitin Sulfate Hydrogels as a Novel Drug-Delivery Mechanism for the Treatment of Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2021 Dec; 28(13):8532-8543.
-
Gupta VK, Sharma NS, Durden B, Garrido VT, Kesh K, Edwards D, Wang D, Myer C, Mateo-Victoriano B, Kollala SS, Ban Y, Gao Z, Bhattacharya SK, Saluja A, Singh PK, Banerjee S. Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer. Cancer Res. 2021 08 01; 81(15):4001-4013.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|